About SemBioSys Genetics Inc. (http://www.sembiosys.com)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets.
This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those anticipated.
These forward-looking statements involve risks and uncertainties including,
but not limited to, changing market conditions, the successful and timely
completion of clinical studies, the establishment of corporate alliances,
the impact of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process and other risks
detailed from time-to-time in the Company's ongoing filings with the
Canadian securities regulatory authorities which filings can be found at
http://www.sedar.com. Given these risks and uncertainties, readers are cautioned
not to place undue reliance on
|SOURCE SemBioSys Genetics Inc.|
Copyright©2008 PR Newswire.
All rights reserved